Dice Therapeutics reports Q4 EPS (51c), consensus (49c)

Reports Q4 cash, cash equivalents and marketable securities totaled $574.2M at December 31. The Company expects its current cash position to fund operations through expected key clinical milestones and into 2026.."We have entered 2023 with strong momentum and continue to make excellent progress advancing our oral IL-17 programs, including our lead product candidate DC-806 and fast follower DC-853," said Kevin Judice, Ph.D., CEO of DICE Therapeutics. "Following the recent U.S. Food and Drug Administration clearance of our investigational new drug application for DC-806, we remain on track to initiate a global Phase 2b clinical trial in the first half of 2023. In addition, we began dosing healthy volunteers in our Phase 1 trial with DC-853 and expect topline data in the second half of 2023. We are also continuing to utilize our DELSCAPE platform to advance our earlier stage research and development (R&D) programs, expanding our pipeline to other validated targets in immunology."